Skip to main content
. Author manuscript; available in PMC: 2021 Jul 21.
Published in final edited form as: J Control Release. 2015 Feb 11;204:20–29. doi: 10.1016/j.jconrel.2015.01.036

Figure 2.

Figure 2.

Dose-dependent enhancement of luciferase transgene expression by the PLK1 inhibitor HMN-214 in PC3-PSMA human prostate cancer and MB49 murine bladder cancer cells following delivery of pGL3.0 plasmid DNA using PEI and 1,4C-1,4Bis polymers. Relative enhancement of luciferase expression (RLUV) compared to the polyplex control is shown in the left panels, while effects of the drug on cell proliferation are shown in the panels on the right side. Asterisks (*) indicate statistically significant difference (student’s T-test) from the corresponding polyplex control (n = 3 independent experiments; p < 0.05).